Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
QL2106 vs Tremfya in Moderate to Severe Plaque Psoriasis
NCT07511647Phase 3Active, not recruiting
- Sponsor
- Qilu Pharmaceutical
- Start
- May 2026
- Primary completion
- Dec 2027
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 3 trial of QL2106 in plaque psoriasis, sponsored by Qilu Pharmaceutical. Started May 2026; status: active, not recruiting.
02
Drugs
QL2106
03
Conditions
plaque psoriasis
Beyond the preview
Go deeper on NCT07511647.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07511647.